RIGL
Rigel Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
5.71 / 10
Netural
Fund flow is strong (7.95/10) with overall, block, medium, large and extra‑large investors net buying, though small investors are net sellers. Analyst sentiment is split: one Strong Buy (100% historic win) and one Neutral (0% win), yielding a neutral consensus.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-05
InstitutionJefferies
Times predicted1
Historical Win Rate100.0%
What is the analyst consensus for RIGL?
- RIGL holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.71/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
